<bill session="113" type="hr" number="161" updated="2013-11-02T06:16:59-04:00">
  <state datetime="2013-04-15">REFERRED</state>
  <status>
    <introduced datetime="2013-04-15"/>
  </status>
  <introduced datetime="2013-04-15"/>
  <titles>
    <title type="official" as="introduced">Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.</title>
  </titles>
  <sponsor id="400340"/>
  <cosponsors>
    <cosponsor id="400004" joined="2013-04-15"/>
    <cosponsor id="412451" joined="2013-04-15"/>
    <cosponsor id="412435" joined="2013-04-15"/>
    <cosponsor id="400249" joined="2013-04-15"/>
    <cosponsor id="400331" joined="2013-04-15"/>
    <cosponsor id="400407" joined="2013-04-15"/>
    <cosponsor id="400435" joined="2013-04-15"/>
  </cosponsors>
  <actions>
    <action datetime="2013-04-15" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2013-04-19">
      <text>Referred to the Subcommittee on Health.</text>
      <committee name="House Committee on Energy and Commerce"/>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" activity="Referral, In Committee"/>
    <committee activity="Referral" code="HSIF14" subcommittee="Health" name="House Energy and Commerce"/>
  </committees>
  <relatedbills>
    <bill relation="unknown" session="113" type="sr" number="97"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug, alcohol, tobacco use"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary>4/15/2013--Introduced.
Expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.</summary>
</bill>
